Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

中文翻译：

---

结核病治疗的全球前景。

结核病（TB）是困扰人类的最古老的感染之一，但仍然是全球排名第一的传染病杀手。尽管有数十年治疗这种疾病的经验，结核病治疗方案甚至需要潜伏感染，仍需要数月的多药治疗。从潜在感染到广泛耐药性（XDR）TB疾病，整个TB范围内的治疗选择都取得了重要的最新进展。此外，新的，有效的药物正在开发过程中脱颖而出，并且正在以多种新的方案在目前进行的多项入组试验中进行测试。现在可以使用更短，更安全的多种形式的结核病治疗方案，或者在我们的近期愿景中。我们回顾了结核病治疗的最新进展，并概述了即将到来的临床试验前景，这将有助于确定全球结核病治疗的未来。